
Bausch Health Companies BHC
$ 6.95
-0.93%
Quarterly report 2024-Q2
added 08-01-2024
Bausch Health Companies General and Administrative Expenses 2011-2025 | BHC
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Bausch Health Companies
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.92 B | 2.62 B | 2.62 B | 2.37 B | 2.55 B | 2.47 B | 2.58 B | 2.81 B | 2.7 B | 2.03 B | 1.31 B | 813 M | 584 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.92 B | 584 M | 2.18 B |
Quarterly General and Administrative Expenses Bausch Health Companies
| 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 832 M | 794 M | - | 715 M | 711 M | 725 M | - | 661 M | 676 M | 622 M | - | 653 M | 685 M | 606 M | - | 572 M | 526 M | 633 M | - | 648 M | 651 M | 587 M | - | 614 M | 642 M | 591 M | - | 623 M | 659 M | 661 M | - | 661 M | 671 M | 813 M | - | 698 M | 686 M | 574 M | - | 504 M | 516 M | 482 M | - | 356 M | 257 M | 242 M | - | 189 M | 185 M | 177 M | - | 135 M | 150 M | 140 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 832 M | 135 M | 549 M |
General and Administrative Expenses of other stocks in the Drug manufacturers industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Alimera Sciences
ALIM
|
18.5 M | - | - | $ 142 M | ||
|
Canopy Growth Corporation
CGC
|
170 M | $ 1.7 | 50.0 % | $ 183 M | ||
|
Aerie Pharmaceuticals
AERI
|
138 M | - | - | $ 754 M | ||
|
Cronos Group
CRON
|
95.9 M | $ 3.24 | 13.51 % | $ 1.69 B | ||
|
Assertio Holdings
ASRT
|
78.6 M | $ 0.77 | -1.79 % | $ 54.7 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
8.53 M | - | 7.5 % | $ 6.35 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
13.2 M | - | 0.86 % | $ 117 M | ||
|
Agile Therapeutics
AGRX
|
10.5 M | - | 10.11 % | $ 58.2 M | ||
|
Aurora Cannabis
ACB
|
119 M | $ 5.36 | 17.8 % | $ 86.3 M | ||
|
Catalent
CTLT
|
935 M | - | - | $ 11.5 B | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
390 M | - | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
58.2 M | - | 2.45 % | $ 38.1 M | ||
|
DURECT Corporation
DRRX
|
14.4 M | - | - | $ 50.1 M | ||
|
Eagle Pharmaceuticals
EGRX
|
107 M | - | -39.89 % | $ 27.7 M | ||
|
Endo International plc
ENDP
|
568 M | - | - | $ 28.9 M | ||
|
Emergent BioSolutions
EBS
|
368 M | $ 11.46 | -2.22 % | $ 587 M | ||
|
Evoke Pharma
EVOK
|
12.2 M | $ 10.97 | 0.18 % | $ 36.7 M | ||
|
Athenex
ATNX
|
44.9 M | - | -23.39 % | $ 1.76 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
181 M | $ 21.38 | -0.05 % | $ 2.03 B | ||
|
Evolus
EOLS
|
198 M | $ 6.99 | 1.09 % | $ 433 M | ||
|
Harrow Health
HROW
|
83.1 M | $ 47.18 | -7.67 % | $ 1.54 B | ||
|
China Pharma Holdings
CPHI
|
1.78 M | $ 1.67 | 11.33 % | $ 29.2 M | ||
|
OrganiGram Holdings
OGI
|
12.8 M | $ 1.88 | 14.72 % | $ 402 M | ||
|
Lannett Company
LCI
|
81 M | - | 1.15 % | $ 7.11 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
11.1 M | $ 2.61 | 4.99 % | $ 36.7 M | ||
|
Neoleukin Therapeutics
NLTX
|
11.2 M | - | - | $ 193 M | ||
|
Organogenesis Holdings
ORGO
|
295 M | $ 4.83 | 1.15 % | $ 636 M | ||
|
Pacira BioSciences
PCRX
|
294 M | $ 26.28 | 2.14 % | $ 1.22 B | ||
|
PetIQ
PETQ
|
196 M | - | 1.64 % | $ 400 M | ||
|
Relmada Therapeutics
RLMD
|
48.9 M | $ 4.12 | -1.67 % | $ 124 M | ||
|
Jupiter Wellness
JUPW
|
39.6 M | - | - | $ 33.6 M | ||
|
Perrigo Company plc
PRGO
|
468 M | $ 13.13 | -2.23 % | $ 1.8 B | ||
|
ProPhase Labs
PRPH
|
34.4 M | $ 0.12 | -15.26 % | $ 1.9 M | ||
|
Radius Health
RDUS
|
131 M | - | - | $ 1.42 B | ||
|
Recro Pharma
REPH
|
21 M | - | -4.76 % | $ 65.3 M | ||
|
Rockwell Medical
RMTI
|
12.1 M | $ 0.93 | -2.37 % | $ 21.7 M | ||
|
Sundial Growers
SNDL
|
38.4 M | $ 2.19 | 24.01 % | $ 3.37 M | ||
|
OptiNose
OPTN
|
79.8 M | - | - | $ 1.08 B | ||
|
PLx Pharma
PLXP
|
40 M | - | -27.8 % | $ 2.56 M | ||
|
SCYNEXIS
SCYX
|
20.9 M | $ 0.64 | -0.02 % | $ 30.6 M | ||
|
Solid Biosciences
SLDB
|
33.3 M | $ 5.85 | -0.34 % | $ 239 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
7.36 M | $ 3.59 | -3.37 % | $ 4.46 M | ||
|
Tricida
TCDA
|
37.6 M | - | - | $ 3.25 M | ||
|
Tilray
TLRY
|
165 M | $ 11.86 | 40.68 % | $ 7.33 B | ||
|
TherapeuticsMD
TXMD
|
8.9 M | $ 1.79 | -2.72 % | $ 18.7 M | ||
|
Zomedica Corp.
ZOM
|
29 M | - | -0.21 % | $ 98 M | ||
|
Veru
VERU
|
31.2 M | $ 2.45 | -4.3 % | $ 330 M | ||
|
Viatris
VTRS
|
4.18 B | $ 11.63 | 0.3 % | $ 14.1 B |